AMRX - Amneal Pharmaceuticals Inc.

-

$undefined

N/A

(N/A)

Amneal Pharmaceuticals Inc. NasdaqGS:AMRX Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Location: 400 Crossing Boulevard, Bridgewater, NJ, 08807, United States | Website: https://www.amneal.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

4.878B

Cash

61.63M

Avg Qtr Burn

N/A

Short % of Float

3.21%

Insider Ownership

46.75%

Institutional Own.

44.26%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PEMRYDI RTU® Details
Small cell lung cancer, Malignant pleural/peritoneal mesothelioma

Approved

Update

RELEUKO® (filgrastim-ayow) Details
Chemotherapy-induced neutropenia

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

BORUZU (Bortezomib) Details
Multiple myeloma, Mantle cell lymphoma

Approved

Quarterly sales

Approved

Quarterly sales

Lisdexamfetamine Dimesylate Details
Attention deficit hyperactivity disorder

Approved

Quarterly sales

Approved

Quarterly sales

PDUFA

Approval decision